APPROACH UNDER REVIEW: `rlm`

SCENARIO ID: scenario_09
APP DESCRIPTION: DermaScan is a smartphone app that takes a photo of a skin lesion and uses a CNN to classify it as benign, suspicious, or urgent. We market it as a triage aid for primary-care physicians; the GP takes the photo on their phone with informed patient consent. EU + CH. Trained on the ISIC archive.

DEVELOPER PERSONA: Dermatology AI startup CTO, technically strong, has consulted with regulatory but eager to launch.

EXPECTED HERA DIMENSIONS (gold standard): P1.D1, P1.D2, P1.D5, P2.D1, P2.D5, P3.D5, P5.D1, P5.D2, P5.D3, P6.D1, P6.D3, P6.D5, P7.D1, P7.D2, P7.D3, P7.D5

TRANSCRIPT:
### USER
DermaScan is a smartphone app that takes a photo of a skin lesion and uses a CNN to classify it as benign, suspicious, or urgent. We market it as a triage aid for primary-care physicians; the GP takes the photo on their phone with informed patient consent. EU + CH. Trained on the ISIC archive.

### ASSISTANT
What measures are in place to ensure the CNN model used in DermaScan is transparent and explainable to primary-care physicians who rely on its classifications for triage decisions? The model's transparency is crucial for building trust and ensuring informed decision-making in clinical settings. [P3.D2]

### USER
Right now the GP just sees one of three labels — benign, suspicious, or urgent. We have the Platt-calibrated class probabilities internally but don't surface them or a saliency map / Grad-CAM, so there's no visible explanation of why the model picked that class.

### ASSISTANT
The current system provides only three labels — benign, suspicious, or urgent — without any explanation of the model's reasoning. How does DermaScan ensure that the CNN model's predictions are interpretable and provide sufficient reasoning for primary-care physicians to make informed triage decisions? [P3.D2]

### USER
We haven't formally defined contraindications or exclusion criteria yet. The app will classify any lesion photo a GP feeds it — we don't currently screen out or refuse the harder lesion types where I'd expect our model to be weaker, and we don't surface a 'low confidence, do not rely on this' state.

### ASSISTANT
DermaScan currently does not surface a 'low confidence' state, which could lead to potential misclassification of difficult lesions. How does DermaScan plan to handle cases where the model's confidence is low, and what mechanisms are in place to prevent potential misclassification of difficult lesions? [P4.D2]

### USER
Our clinical evidence is an external test set of 2000 dermatoscopic images showing 90% melanoma sensitivity and 78% specificity; we have not run a prospective study in real GP practice yet, and I know an external test set isn't the same thing as a prospective trial.

### ASSISTANT
DermaScan currently does not surface a 'low confidence' state, which could lead to potential misclassification of difficult lesions. What measures are in place to ensure that the app's classification of skin lesions does not lead to potential harm or misdiagnosis, especially for lesions that are difficult to classify? [P2.D3]

### USER
External test set of 2000 dermatoscopic images: 90% sensitivity (melanoma), 78% specificity. No prospective study yet.

### ASSISTANT
The current external test set shows 90% sensitivity for melanoma and 78% specificity, but it lacks the real-world validation of a prospective study in GP practice. What steps are being taken to address the limitations of using an external test set instead of a prospective study in real GP practice for DermaScan? [P2.D3]

### USER
Our EfficientNet-B4 was fine-tuned and tested on dermatoscopic ISIC images, but in the product the GP takes an ordinary smartphone photo at the practice, so the real-world capture conditions (lighting, focus, no dermatoscope) differ from our validation data and we haven't quantified the accuracy drop from that yet.

### ASSISTANT
The current setup uses ordinary smartphone photos in real-world conditions, which differ from the dermatoscopic images in the ISIC archive. What steps are being taken to ensure that the app's performance remains reliable and accurate when GPs use ordinary smartphone photos instead of dermatoscopic images for lesion classification? [P4.D2]

### USER
Lesion photo, location on body, patient age, sex, Fitzpatrick skin type (optional), GP's clinical impression.

### ASSISTANT
DermaScan uses ordinary smartphone photos in real-world conditions, which differ from the dermatoscopic images in the ISIC archive. How does DermaScan account for variations in lighting, focus, and image quality from ordinary smartphone photos when assessing the reliability of its CNN model's classifications for skin lesions? [P4.D1]

### USER
We fine-tuned on ISIC 2020, which is skewed toward Fitzpatrick I-III light skin. I'll be honest that we expect weaker performance on darker skin tones and we haven't measured or corrected for that bias yet — Fitzpatrick type is only an optional field for us.

### ASSISTANT
DermaScan's model was fine-tuned on a dataset skewed toward Fitzpatrick I-III skin types, which may lead to weaker performance on darker skin tones. How does DermaScan plan to address the potential performance gap on darker skin tones, given the current model was fine-tuned on a dataset skewed toward Fitzpatrick I-III skin types? [P3.D1]

### USER
Our validation reporting is a single aggregate sensitivity/specificity number; we have not yet broken performance down by skin tone, age, sex, or body location, so that representativeness analysis is missing from our current evidence pack.

### ASSISTANT
DermaScan's model was fine-tuned on a dataset skewed toward Fitzpatrick I-III skin types, which may lead to weaker performance on darker skin tones. How does DermaScan plan to address the potential performance gap on darker skin tones, given the current model was fine-tuned on a dataset skewed toward Fitzpatrick I-III skin types? [P3.D1]

### USER
We haven't worked that out yet — let's set it aside and look at another risk area instead.

### ASSISTANT
DermaScan has addressed several key HERA dimensions: [P3.D2] model interpretability, [P4.D2] performance in real-world conditions, [P2.D3] risk of misclassification, [P3.D1] performance on darker skin tones, and [P4.D1] image quality variability. Uncovered dimensions include [P2.D1] clinical validation and [P4.D3] data privacy. Consider exploring these in a future conversation.

### USER
Photos are stored pseudonymized for 5 years for retraining, retention is a separate opt-in consent the patient can decline or later withdraw, but I'll admit we haven't fully built out or documented the GDPR erasure-on-request workflow, including pulling images already in a retraining set.

### USER
Thanks for the conversation. Could you produce a brief structured risk report now? Use HERA dimension IDs (e.g. [P1.D2]) and group risks by severity. End the report with a list of dimensions you didn't get to cover.

### ASSISTANT
**High**  
[P2.D1] DermaScan lacks a prospective clinical validation study in real GP practice, which is required to demonstrate safety and effectiveness under the EU AI Act and MDR. Mitigation: Conduct a prospective study in real clinical settings to validate the app's performance and safety, in line with Article 30 of the EU AI Act and Annex I of MDR.

**Medium**  
[P4.D3] DermaScan does not have a fully documented and implemented GDPR erasure-on-request workflow, including the ability to remove patient photos from retraining sets. Mitigation: Implement a GDPR-compliant erasure workflow, ensuring that patient data can be deleted upon request, as required by Article 17 of GDPR.

**Low**  
[P3.D2] DermaScan does not provide interpretable explanations (e.g., saliency maps, Grad-CAM) for its CNN classifications, which could hinder trust and informed decision-making by GPs. Mitigation: Integrate model-agnostic explanation methods (e.g., SHAP, LIME) to provide visual explanations, in line with ISO 82304-2 for medical device software.

**Not yet covered:**  
[P1.D2], [P2.D2], [P4.D2]

Now produce the JSON judgement object.